Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time
Oncotype DX (oDX) is used to predict recurrence and indicate response to chemotherapy in patients with early-stage breast cancer (BC). We evaluated the relationship between age (< 50 vs. ≥ 50 years), recurrence score (RS), chemotherapy use, and trends of oDX testing over time.
Using the National Cancer Database, we identified women with T1/T2, N0, estrogen receptor-positive BC from 2009 to 2014. We stratified patients by age (< 50 and ≥ 50 years) and RS (low: < 18; intermediate: 18–30; and high: > 30), and compared demographics, tumor characteristics, and chemotherapy recommendations. Management trends were also assessed.
From 2009 to 2014, a total of 377,725 cases met the eligibility criteria for oDX testing; 115,052 (30.5%) patients had oDX, and 60,804 (16.1%) were < 50 years of age. The majority had low RS and T1N0 disease. Patients < 50 years of age were more likely to be recommended chemotherapy than those ≥ 50 years of age, regardless of RS (p ≤ 0.001), and were more likely to ultimately undergo chemotherapy (p < 0.001). When stratified by year, oDX utilization increased. There was a decreasing trend in chemotherapy recommendations in both the low- and intermediate-RS groups for both age groups (all p = 0.001), with no change in the high-RS group (< 50 years: p = 0.52; ≥ 50 years: p = 0.67). Univariate and multivariate analyses demonstrated that patients < 50 years of age and those with a higher RS were more likely to be recommended chemotherapy (p < 0.001).
The testing of oDX in BC has significantly increased since first implemented. Results from additional studies such as TAILORx will clarify the current discordant practice patterns between low oDX RSs and adjuvant chemotherapy recommendations.
LC conceptualized this project, and LC, JT, and ADW designed the project. ADW performed data acquisition and data analysis. LC, JT, and ADW performed interpretation, and LC drafted the initial manuscript. RA, LC, SR, JT, and ADW assisted in critical revision of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
This study was partly funded by the National Cancer Institute (NCI) Cancer Center Support Grant [2-P30-CA-016520-35] (JT), Breast Cancer Alliance Research Foundation (JT), and the Breast Cancer Immunotherapy Funds (JT and ADW).
Austin D. Williams, Sylvia A. Reyes, Renee L. Arlow, Julia Tchou, and Lucy M. De La Cruz have no financial relationships or conflicts of interest to disclose relevant to this article.
- 2.Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefGoogle Scholar
- 3.Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.CrossRefGoogle Scholar
- 7.NCCN. Evidence-based cancer guidelines, oncology drug compendium, oncology continuing medical education. https://www.nccn.org/. Accessed 14 Apr 2018.
- 11.American Joint Committee on Cancer (AJCC) Cancer staging manual, 8th ed. https://cancerstaging.org/references-tools/deskreferences/Pages/Breast-Cancer-Staging.aspx. Accessed 3 Apr 2018.
- 12.US Breast Cancer Statistics. http://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed 10 Apr 2018.